10-Q: Aditxt Inc. Q1 2026 Financials Show Significant Net Loss

Aditxt, Inc. reported a substantial net loss of $16.19 million for the first quarter of 2026, with minimal revenue and ongoing concerns about its ability to continue as a going concern.

Summary

• Aditxt, Inc. reported a net loss of $16,189,200 for the three months ended March 31, 2026, a significant increase from the $5,952,465 net loss in the same period of 2025.
• Revenue for the quarter was $12,159, up from $1,018 in the prior year's quarter, with cost of goods sold at $9,291.
• Operating expenses totaled $4,364,731 for the quarter, a decrease from $5,608,399 in Q1 2025, primarily due to lower general and administrative expenses.
• Other expenses were substantial at $11,827,337, largely driven by an $11,800,798 change in the fair value of derivative liabilities.
• The company's cash balance stood at $268,852 as of March 31, 2026, with a working capital deficit of $12,491,562, raising substantial doubt about its ability to continue as a going concern.
• The company received a Nasdaq Staff Determination letter on May 6, 2026, indicating intent to delist securities due to a bid price below $1.00, despite recent reverse stock splits.
• Aditxt is appealing the delisting determination and is actively pursuing capital raising transactions to fund operations and meet its capital needs.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a very negative filing due to the significant increase in net loss, critically low cash reserves, ongoing going concern doubts, and the imminent threat of Nasdaq delisting.

Positives

• Revenue increased to $12,159 in Q1 2026 from $1,018 in Q1 2025, partly due to the acquisition of Ignite.
• Operating expenses decreased to $4,364,731 in Q1 2026 from $5,608,399 in Q1 2025.
• The company received a Nasdaq notification on April 1, 2026, stating it now complies with certain continued listing standards based on its Form 10-K filing.
• Preclinical data for ADI-100 (Adimune) shows potential effectiveness in restoring durable tolerance for Type-1 Diabetes and no observed drug toxicity.
• Pearsanta has two product candidates in development for prostate cancer diagnosis and endometriosis detection.
• Adivir, Inc. is focused on building a portfolio of antiviral and antimicrobial solutions for infectious diseases.

Negatives

• A significant net loss of $16,189,200 was reported for Q1 2026, compared to $5,952,465 in Q1 2025.
• The company has a substantial accumulated deficit of $225,756,495 as of March 31, 2026.
• Cash and cash equivalents were only $268,852 as of March 31, 2026, insufficient to fund operations for the next 12 months.
• The company is over 90 days past due on a significant amount of vendor obligations, with approximately $5.8 million of accounts payable over 90 days past due.
• The company received a Nasdaq Staff Determination letter on May 6, 2026, indicating intent to delist its securities from The Nasdaq Capital Market.
• The company is not eligible for an additional compliance period for the bid price rule due to multiple reverse stock splits within the past two years.
• The May 2025 Note is in default status as of March 31, 2026.
• The Richmond, Virginia lease is in default due to an outstanding security deposit of $159,375.
• The Vertalo Action lawsuit seeks alleged unpaid fees of $300,000, warrants, and other damages.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to its limited operating history, significant net losses, and insufficient cash reserves.
• The company may not be able to obtain necessary additional capital on acceptable terms, or at all, which could force it to discontinue operations.
• Delisting from Nasdaq could significantly impact the value and liquidity of its common stock, and adversely affect its ability to obtain financing.
• The company faces substantial competition in the biotechnology and pharmaceutical sectors.
• Reliance on licenses from Loma Linda University and Stanford carries risks, as these licenses are revocable under certain circumstances, including failure to meet payment and milestone deadlines.
• Loss of CLIA certification or state laboratory licenses would prevent the company from offering its assays.
• The company has generated no significant revenue from commercial sales to date, and future profitability is uncertain.
• The company may need to raise additional funding, which could be dilutive to existing shareholders.
• Regulatory approval processes are expensive, time-consuming, and uncertain, potentially preventing commercialization of product candidates.
• Delays in clinical studies could lead to additional costs and may prevent regulatory approval.
• Adverse events involving products could lead to delays or denials of clearance or product recalls.
• The company does not expect to pay dividends in the foreseeable future.
• The company has issued a significant number of convertible preferred stock and warrants, and future issuances may dilute ownership and pressure stock price.
• The company may engage in future acquisitions or strategic transactions that require additional financing and could distract management.

Future Outlook

The company's future outlook is heavily dependent on its ability to secure significant additional capital to fund its ongoing operations, clinical trials, and to address its substantial outstanding liabilities. The company expects to continue incurring significant operating losses for the foreseeable future and its ability to achieve profitability is uncertain. The ongoing Nasdaq delisting proceedings and the need to address vendor obligations and debt present significant challenges to future operations and financing.

Management Comments

• "We believe the world needs—and deserves—a new approach to innovation that harnesses the power of large groups of stakeholders who work together to ensure that the most promising innovations reach people who need them most."
• "The socialization of innovation through engaging stakeholders in every aspect of it, is key to transforming more innovations, more rapidly, and more efficiently."
• "We believe our remaining funds on hand will not be sufficient to fund our operations for the next 12 months and such creates substantial doubt about our ability to continue as a going concern beyond one year."
• "We expect to incur additional net expenses over the next several years as we continue to maintain and expand our existing operations. The amount of future losses and when, if ever, we will achieve profitability are uncertain."

Industry Context

StockSavvy.ai notes that Aditxt's Q1 2026 results reflect the high-risk, high-reward nature of early-stage biotechnology companies. The significant net loss and going concern issues are common in this sector, where substantial investment is required for R&D and clinical trials before any revenue can be generated. The company's focus on immune modulation and cancer diagnostics places it in competitive but potentially high-growth areas.

Comparison to Industry Standards

• The net loss of $16.19 million for the quarter is substantial, even for a biotechnology company, and significantly exceeds the net loss of $5.95 million in the prior year's quarter. This indicates a worsening financial performance in the short term.
• The company's revenue of $12,159 is extremely low, highlighting the early-stage nature of its commercialization efforts. Many clinical-stage biotech companies generate minimal to no revenue, but Aditxt's revenue is particularly negligible.
• The significant increase in derivative liabilities to $35.45 million from $2 is a major concern, indicating complex financial instruments and potential future obligations or valuation adjustments that are impacting the balance sheet.
• The company's cash balance of $268,852 is critically low, falling far below the typical cash runway required for clinical-stage biotech companies, which often aim for 12-18 months of operating expenses.
• The Nasdaq delisting threat is a severe indicator of financial distress, as maintaining a minimum bid price is a fundamental requirement for listing on major exchanges. Companies like Sorrento Therapeutics have faced similar delisting threats due to financial instability.

Legal Proceedings

• Vertalo, Inc. filed a lawsuit alleging breach of contract, seeking unpaid fees of $300,000, warrants, and other damages. Aditxt disputes the allegations and intends to defend vigorously.

Related Party Transactions

• The acquisition of Ignite Proteomics, LLC on March 11, 2026, involved 36,000 shares of Series A-2 Convertible Preferred Stock and cash. Certain investors involved had pre-existing financial interests in Aditxt, making it a related party transaction.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future capital raises and the conversion/exercise of outstanding preferred stock and warrants.
• Shareholders are at risk of losing their entire investment if the company cannot continue as a going concern or secure necessary funding.
• Creditors and vendors face risks of delayed or non-payment, with significant overdue vendor obligations reported.
• Employees may face uncertainty regarding job security given the company's financial precariousness and potential delisting.

Next Steps

• Appeal the Nasdaq Staff Determination regarding delisting.
• Continue pursuing capital raising transactions to fund operations and meet capital needs.
• Submit IND package to the FDA for the ADI-100 product candidate for Stiff Person Syndrome.
• Continue development of Mitomic Prostate Test (MPT) and Mitomic Endometriosis Test (MET).
• Advance the Adductomics Technology platform toward clinical and commercial applications.
• Address overdue vendor obligations and existing debt.
• Seek regulatory approval for clinical trials in Germany for psoriasis and T1D.

Key Dates

Recommendation

The company exhibits severe financial distress, including a substantial increase in net loss, critically low cash reserves, significant overdue payables, and a high probability of Nasdaq delisting. These factors, combined with the ongoing need for substantial capital raises that will likely be dilutive, present an extremely high risk to investors. The company's ability to continue as a going concern is in serious doubt.

Keywords

Aditxt, SEC Filing, 10-Q, Quarterly Report, Financial Results, Net Loss, Going Concern, Nasdaq Delisting, Biotechnology, Drug Development, Clinical Trials, Capital Raise, Derivative Liabilities, Preferred Stock, Warrants